PLIANT THERAPEUTICS INC. - COMMON STOCK

Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis

13 11 2023 16:30:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

09 11 2023 16:05:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

08 11 2023 08:00:01 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1

06 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer

31 10 2023 16:03:07 提供 Nasdaq GlobeNewswire

Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023

19 10 2023 08:00:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer

16 10 2023 16:05:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

26 9 2023 07:30:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis

25 9 2023 16:05:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023

11 9 2023 08:00:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

30 8 2023 08:00:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023

28 8 2023 16:05:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

09 8 2023 16:03:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis

09 8 2023 08:00:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

23 6 2023 07:30:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

24 5 2023 08:00:01 提供 Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Events

10 5 2023 08:05:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

09 5 2023 16:02:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

30 4 2023 14:10:28 提供 Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference

12 4 2023 08:01:00 提供 Nasdaq GlobeNewswire